Elementis plc shares climbed 5.7% on Tuesday after the specialty chemicals company finalised the sale of its pharmaceutical manufacturing unit to Associated British Foods.
The divested business was sold for an enterprise value of €34.3m (c.$39.8m). Elementis said net cash proceeds after transaction costs will be approximately €30m (c.$35m).
Return of proceeds to shareholders
Elementis said it intends to return the entire $35m in net proceeds to shareholders via a share buyback programme, which the company expects to begin as soon as practicable.
Strategic repositioning
The company described the transaction as a strategic move that repositions Elementis as a pure-play specialty chemicals business concentrated on specialty additives serving the Personal Care and Coatings markets. Management said the sale will improve adjusted operating margin at both the Group level and within the Personal Care division, while also reducing future capital intensity.
Board rationale
The Board pointed to Elementis’s robust balance sheet, a strong first quarter showing and an unchanged outlook for the year as factors supporting the decision to return proceeds to shareholders. The company had previously issued a trading update on April 29.
Luc van Ravenstein, chief executive officer of Elementis, said: "The Transaction further strengthens the quality of our portfolio and sharpens our focus on our core markets."
Buyer and future prospects for the unit
The pharmaceutical manufacturing business was sold to Associated British Foods, which Elementis said offers a global pharmaceutical platform and established customer relationships expected to support the unit’s continued growth.
Summary
Elementis has completed the sale of its pharmaceutical manufacturing unit to Associated British Foods for an enterprise value of €34.3m (c.$39.8m), yielding roughly €30m (c.$35m) in net cash proceeds. The company will return the full $35m to shareholders through a share buyback programme and will concentrate on specialty additives in Personal Care and Coatings, with anticipated margin and capital-intensity benefits.
Key points
- Sale completed for an enterprise value of €34.3m (c.$39.8m) with net cash proceeds of about €30m (c.$35m).
- Elementis will return the full $35m net proceeds to shareholders via a share buyback programme expected to begin as soon as practicable.
- The transaction positions Elementis as a pure-play specialty chemicals company focused on additives for Personal Care and Coatings and is expected to improve adjusted operating margins and reduce future capital intensity.
Risks and uncertainties
- The timing of the share buyback programme is described as "as soon as practicable," leaving the start date uncertain - this could affect shareholder returns timing.
- While the Board has cited a robust balance sheet and a strong first quarter, the group’s outlook for the year is described as unchanged, leaving the company exposed to any future operational or market developments that might alter that outlook.
- The future performance of the sold pharmaceutical manufacturing business now depends on Associated British Foods’ platform and customer relationships to support its growth, an outcome referenced but not guaranteed in Elementis’s statement.
Markets and sectors impacted
- Specialty chemicals - Elementis refocuses on additives for Personal Care and Coatings.
- Personal Care and Coatings markets - the company expects margin improvement in these end-markets.
- Equity markets - Elementis shares rose following the announcement and a buyback plan.